OR WAIT null SECS
Novavax and the Government of Canada will finalize an advanced purchase agreement under which Novavax will supply doses of NVX-CoV2373 to Canada beginning in the second quarter of 2021.
Novavax announced on Aug. 31, 2020 that it will supply up to 76 million doses of its COVID-19 vaccine candidate, NVX-CoV2373, to the Government of Canada.
Under the terms of the agreement, Novavax and the Government of Canada will finalize an advanced purchase agreement under which Novavax will supply doses of NVX-CoV2373 to Canada beginning in the second quarter of 2021, a Novavax press release said.
The vaccine candidate is currently involved in several Phase II clinical trials in the United States and Australia to evaluate its safety and immunogenicity, the press release said. An additional Phase IIb trial for the drug began in South Africa in August 2020.
“We are pleased to work with the Canadian government on supply of our COVID-19 vaccine, an essential step to ensure broad access of our vaccine candidate,” said Stanley C. Erck, president and CEO of Novavax, in the press release. “We are moving forward with clinical development of NVX-CoV2373 with a strong sense of urgency in our quest to deliver a vaccine to protect the world.”
“We are pleased to announce this agreement with Novavax, which will give Canadians access to a promising COVID-19 vaccine candidate. This is an important step in our government’s efforts to secure a vaccine to keep Canadians safe and healthy, as the global pandemic evolves,” added the Honourable Anita Anand, minister of Public Services and Procurement, Government of Canada, in the press release.